Paper9929751
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Iliadis EA and 1 other. Clin Cardiol, 1999. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Papers, record 9929751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9929751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gemfibrozil | Major topic |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | Major topic |
| Hyperlipidemias | Major topic |
| Pravastatin | Major topic |
| Cholesterol, HDL | |
| Cholesterol, LDL | |
| Creatine | |
| Creatine Kinase | |
| Drug Therapy, Combination | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Liver Function Tests | |
| Male | |
| Middle Aged | |
| Retrospective Studies | |
| Safety | |
| Treatment Outcome | |
| Triglycerides |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1615846 | Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. | Am J Cardiol | 1992 | https://conductscience.org/library/papers/1615846 | PubMed |
| 2 | 2006579 | Rhabdomyolysis associated with lovastatin and erythromycin use. | West J Med | 1991 | https://conductscience.org/library/papers/2006579 | PubMed |
| 3 | 2355431 | Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. | JAMA | 1990 | https://conductscience.org/library/papers/2355431 | PubMed |
| 4 | 3275892 | Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. | N Engl J Med | 1988 | https://conductscience.org/library/papers/3275892 | PubMed |
| 5 | 3290520 | Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. | JAMA | 1988 | https://conductscience.org/library/papers/3290520 | PubMed |
| 6 | 3421570 | Lovastatin, nicotinic acid, and rhabdomyolysis. | Ann Intern Med | 1988 | https://conductscience.org/library/papers/3421570 | PubMed |
| 7 | 4337382 | Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Clin Chem | 1972 | https://conductscience.org/library/papers/4337382 | PubMed |
| 8 | 7624744 | [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity]. | Schweiz Med Wochenschr | 1995 | https://conductscience.org/library/papers/7624744 | PubMed |
| 9 | 7637734 | Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. | N Engl J Med | 1995 | https://conductscience.org/library/papers/7637734 | PubMed |
| 10 | 7663035 | Recent advances: the cytochrome P450 enzymes. | Ann Pharmacother | 1995 | https://conductscience.org/library/papers/7663035 | PubMed |
| 11 | 8059735 | Safety of combined pravastatin-gemfibrozil therapy. | Am J Cardiol | 1994 | https://conductscience.org/library/papers/8059735 | PubMed |
| 12 | 8420296 | Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. | Am J Med | 1993 | https://conductscience.org/library/papers/8420296 | PubMed |
| 13 | 8498994 | Gemfibrozil-lovastatin-associated myalgia. | Am J Cardiol | 1993 | https://conductscience.org/library/papers/8498994 | PubMed |
| 14 | 8531308 | Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. | JAMA | 1996 | https://conductscience.org/library/papers/8531308 | PubMed |
| 15 | 8576954 | Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. | J Mol Cell Cardiol | 1995 | https://conductscience.org/library/papers/8576954 | PubMed |
| 16 | 8728350 | Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. | J Clin Pharmacol | 1996 | https://conductscience.org/library/papers/8728350 | PubMed |
| 17 | 8737761 | In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. | Eur J Clin Pharmacol | 1996 | https://conductscience.org/library/papers/8737761 | PubMed |
| 18 | 8815751 | Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. | Ann Intern Med | 1996 | https://conductscience.org/library/papers/8815751 | PubMed |
| 19 | 9002485 | Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. | JAMA | 1997 | https://conductscience.org/library/papers/9002485 | PubMed |
| 20 | 9172950 | Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. | Drug Metab Dispos | 1997 | https://conductscience.org/library/papers/9172950 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 19636324 | Myopathy with statin-fibrate combination therapy: clinical considerations. | Nat Rev Endocrinol | 2009 | https://conductscience.org/library/papers/19636324 | PubMed |
| 17410478 | Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation. | J Inherit Metab Dis | 2007 | https://conductscience.org/library/papers/17410478 | PubMed |
| 15485608 | Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story. | Curr Cardiol Rep | 2004 | https://conductscience.org/library/papers/15485608 | PubMed |
| 12762976 | Combination lipid-lowering therapy in diabetes. | Curr Diab Rep | 2003 | https://conductscience.org/library/papers/12762976 | PubMed |
| 12150329 | Statins and the risk of rhabdomyolysis. | J Endocrinol Invest | 2002 | https://conductscience.org/library/papers/12150329 | PubMed |
| 11487448 | Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. | Curr Atheroscler Rep | 2001 | https://conductscience.org/library/papers/11487448 | PubMed |
| 10980849 | Combination drug therapy for combined hyperlipidemia. | Curr Cardiol Rep | 1999 | https://conductscience.org/library/papers/10980849 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CMPK1 | 51727 | PubTator's text mining | https://conductscience.org/library/genes/51727 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9929751
GET https://conductscience.org/api/papers/v1/9929751/references?page=2